Trial reportJournal of diabetes science and technology2011
A controlled study of the effectiveness of an adaptive closed-loop algorithm to minimize corticosteroid-induced stress hyperglycemia in type 1 diabetes.
Trial report in Journal of diabetes science and technology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01552603 (Sensor-controlled Insulin- and Glucagon Delivery in Subjects With Type 1 Diabetes), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Sensor-controlled Insulin- and Glucagon Delivery in Subjects With Type 1 Diabetes: Testing of an Automated System in a Supervised Inpatient Setting
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- A systematic review of glucocorticoid use in type 1 diabetes: Glycaemic effects and clinical management strategies.Diabetes, obesity & metabolism · 2026Pooled it
- Outpatient Randomized Crossover Automated Insulin Delivery Versus Conventional Therapy with Induced Stress Challenges.Diabetes technology & therapeutics · 2022Trial
- Quantification of the glycemic response to microdoses of subcutaneous glucagon at varying insulin levels.Diabetes care · 2014Trial
- Outpatient glycemic control with a bionic pancreas in type 1 diabetes.The New England journal of medicine · 2014Trial
- Autonomous and continuous adaptation of a bihormonal bionic pancreas in adults and adolescents with type 1 diabetes.The Journal of clinical endocrinology and metabolism · 2014Trial
- Model-based closed-loop glucose control in type 1 diabetes: the DiaCon experience.Journal of diabetes science and technology · 2013Trial
- Fully closed-loop systems: can people with type 1 diabetes just do it? Insights from open-source systems.Diabetologia · 2026Review
- Detecting the metabolic transition to personalize nutritional timing: model development and preliminary validation in a large ICU cohort.Critical care (London, England) · 2026Article
- Design and Evaluation of a Robust PID Controller for a Fully Implantable Artificial Pancreas.Industrial & engineering chemistry research · 2015Article
- Automated control of an adaptive bihormonal, dual-sensor artificial pancreas and evaluation during inpatient studies.IEEE transactions on bio-medical engineering · 2014Article
- Closed-loop artificial pancreas systems: engineering the algorithms.Diabetes care · 2014Article
- A review of artificial pancreas technologies with an emphasis on bi-hormonal therapy.Diabetes, obesity & metabolism · 2013Review
- Challenges and Recent Progress in the Development of a Closed-loop Artificial Pancreas.Annual reviews in control · 2012Article
- Use of a food and drug administration-approved type 1 diabetes mellitus simulator to evaluate and optimize a proportional-integral-derivative controller.Journal of diabetes science and technology · 2012Article
- Safe glycemic management during closed-loop treatment of type 1 diabetes: the role of glucagon, use of multiple sensors, and compensation for stress hyperglycemia.Journal of diabetes science and technology · 2011Review
- Factors affecting the success of glucagon delivered during an automated closed-loop system in type 1 diabetes.Journal of diabetes and its complicationsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
To be effective in type 1 diabetes, algorithms must be able to limit hyperglycemic excursions resulting from medical and emotional stress. We tested an algorithm that estimates insulin sensitivity at regular intervals and continually adjusts gain factors of a fading memory proportional-derivative (FMPD) algorithm. In order to assess whether the algorithm could appropriately adapt and limit the degree of hyperglycemia, we administered oral hydrocortisone repeatedly to create insulin resistance. We compared this indirect adaptive proportional-derivative (APD) algorithm to the FMPD algorithm, which used fixed gain parameters. Each subject with type 1 diabetes (n = 14) was studied on two occasions, each for 33 h. The APD algorithm consistently identified a fall in insulin sensitivity after hydrocortisone. The gain factors and insulin infusion rates were appropriately increased, leading to satisfactory glycemic control after adaptation (premeal glucose on day 2, 148 ± 6 mg/dl). After sufficient time was allowed for adaptation, the late postprandial glucose increment was significantly lower than when measured shortly after the onset of the steroid effect. In addition, during the controlled comparison, glycemia was significantly lower with the APD algorithm than with the FMPD algorithm. No increase in hypoglycemic frequency was found in the APD-only arm. An afferent system of duplicate amperometric sensors demonstrated a high degree of accuracy; the mean absolute relative difference of the sensor used to control the algorithm was 9.6 ± 0.5%. We conclude that an adaptive algorithm that frequently estimates insulin sensitivity and adjusts gain factors is capable of minimizing corticosteroid-induced stress hyperglycemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.